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Background: No study has simultaneously investigated the impacts of migraine and anxiety disorders on painful
physical symptoms (PPS) among patients with major depressive disorder (MDD). The study aimed to investigate this
issue.
Methods: This open-label study enrolled 155 outpatients with MDD, who were then treated with venlafaxine
75 mg per day for four weeks. Eighty-five participants with good compliance completed the treatment. Migraine
was diagnosed according to the International Classification of Headache Disorders. MDD and anxiety disorders were
diagnosed using the Structured Clinical Interview for DSM-IV-TR. The visual analog scale (VAS) was used to evaluate
the severity of eight PPS. Multiple linear and logistic regressions were used to investigate the impacts of migraine
and anxiety disorders on PPS.
Results: Compared with patients without migraine, patients with migraine had a greater severity of PPS at baseline
and post-treatment. After controlling for demographic variables and depressive severity, migraine independently
predicted the intensities of eight PPS at baseline and four PPS post-treatment. Moreover, migraine independently
predicted poorer treatment responses of chest pain and full remission of pains in the head, chest, neck and/or
shoulder. Anxiety disorders predicted less full remission of pains in the abdomen and limbs.
Conclusion: Migraine and anxiety disorders have negative impacts on PPS among patients with MDD. Integrating
the treatment of migraine and anxiety disorders into the management of depression might help to improve PPS
and the prognosis of MDD.
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Depression and painful physical symptoms (PPS) are closely
related and interact [1,2]. PPS are common among patients
with major depressive disorder (MDD) [1-5]. MDD patients
with PPS have a greater severity of depression [3,5], a poorer
quality of life [6,7], and an increased suicidal risk [8].
Moreover, PPS also has negative impacts on the treat-
ment response of depression [9,10].
Migraine is common among patients with MDD and is
related to other PPS [11-14]. MDD patients with migraine
are associated with greater severities of depression and* Correspondence: sjwang@vghtpe.gov.tw
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in any medium, provided the original work is panxiety and a poorer health-related quality of life [11,13,15].
Migraine is an independent factor predicting somatic symp-
toms among patients with MDD [16]. Moreover, migraine
also has negative impacts on the recovery of health-related
quality of life among MDD patients [15].
Patients with depression are often comorbid with anx-
iety, which is related to a greater severity and a poorer
treatment prognosis [17,18]. Anxiety disorders also inter-
act with PPS [19-21]; for example, a patient with general-
ized anxiety disorder (GAD) has a greater severity of PPS
as compared with a control [21].
As described above, MDD, migraine, anxiety disorders,
and PPS are closely related and interact [1,2,14,21,22].
Although many studies have investigated the impacts ofOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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[12,16-18,23], no study has reported the impacts of mi-
graine and anxiety disorders on PPS among patients
with MDD, to the best of our knowledge. Investigating
the above issue is mandatory. If migraine and anxiety
disorders are important factors related to PPS among
patients with MDD, treatment of migraine and anxiety
disorders might directly or indirectly improve PPS.
There is a possibility that improvement of PPS might
be helpful for improving the prognosis of depression,
because PPS have a significantly negative impact on
the prognosis of patients with MDD [3,5-10]. There-
fore, the purpose of this study was to investigate the
impacts of migraine and anxiety disorders on PPS
among patients with MDD. We hypothesized that mi-
graine and anxiety disorders have negative impacts on
PPS among patients with MDD.
Methods
Subject enrollment
This project was conducted from September 2005 to
August 2007 in the psychiatric outpatient clinics of
Chang Gung Memorial Hospital, a medical center in
northern Taiwan. The project was approved by the Insti-
tutional Review Board of the same hospital. Study partic-
ipants were recruited from consecutive outpatients aged
18–65 years who had not taken antidepressants or other
psychotropic drugs within the previous four weeks. MDD
and anxiety disorders were diagnosed using the Structured
Clinical Interview for DSM-IV-text revision (TR) Axis I
Disorders [24]. Patients who met the DSM-IV-TR criteria
for MDD and were experiencing a current major depres-
sive episode were considered eligible subjects [25]. To
prevent depression and somatic symptoms from being
confounded by other medical conditions, substance abuse,
or psychotic symptoms, the following exclusion criteria
were established: 1) a history of substance dependence or
abuse without full remission in the previous month; 2)
psychotic symptoms, catatonic features, or severe psy-
chomotor retardation with obvious difficulty in being
interviewed; and 3) chronic medical diseases such as
hypertension, diabetes mellitus, and other medical dis-
eases, except for headaches. Written informed consent,
based on the guidelines regulated in the Declaration of
Helsinki, was obtained from all subjects prior to study
enrollment following an in-depth explanation of the
procedures.
The study was designed as an open-label study and
the eligible subjects were informed about the following
issues: 1) Antidepressants used in the study have been
proven for the treatment of depression; 2) The period
of observation with a fixed-dosage antidepressant (ven-
lafaxine extended-release, one 75 mg capsule per day)
was four weeks; 3) Subjects were educated regardingdepression and treatment issues. An information sheet
was provided to ensure that all subjects received the
same information.Assessment of headaches
All patients completed a structured headache intake form,
which was designed to meet the operational criteria of the
International Classification of Headache Disorders, 2nd
edition (ICHD-2) [26]. Questions regarding headache
frequency, intensity, pattern, duration, location, aura,
aggravation by physical activities, nausea, vomiting,
photophobia, phonophobia, precipitating factors and
painkiller use were included. An experienced head-
ache specialist (SJW), blind to the psychiatric evalu-
ation results, interviewed all patients after they had
completed the headache intake form and made head-
ache diagnoses. Then, the headache diagnoses were
updated to ICHD-3 beta [27]. Subjects who fulfilled
the criteria of migraine without aura and/or migraine
with aura were categorized as the “migraine” group,
while the other patients were classified as the “non-
migraine” group.Assessment of anxiety disorders
One psychiatrist, blind to the diagnoses of headaches and
the psychometric assessment results, used the Structured
Clinical Interview to diagnose the following anxiety
comorbidities: panic disorder, agoraphobia, social phobia,
specific phobia, post-traumatic stress disorder, obsessive–
compulsive disorder, and GAD [24]. Subjects with any one
of the anxiety comorbidities in a current episode or partial
remission were categorized as the “anxiety disorders”
group, while the others were categorized as the “non-
anxiety disorders” group.Instruments
The Hamilton Depression Rating Scale (HAMD) was used
to evaluate the severity of depression [28]. Subjects evalu-
ated their average pain intensity during the previous week
using a visual analog scale (VAS), with 0 representing “no
pain” and 10 representing “pain as severe as I can im-
agine.” The number of days suffered from each pain in the
past week was recorded. Eight pains were evaluated, in-
cluding pain in bone and/or joints (bone/joints), head,
back, abdomen, chest, neck and/or shoulder (neck/shoul-
der), general muscle, and limbs. The improvement per-
centage (IP) of pain intensity was calculated by (VAS
scores at baseline – VAS scores at the follow-up) × 100% /
VAS scores at baseline. An IP of pain intensity ≥50 fol-
lowing the four-week treatment period was defined as
“treatment response” and an IP =100 was defined as
“full remission”.
Table 1 Demographic variables and comorbidities among
155 patients with major depressive disorder
Total Treatment group Withdrawal group
Case number 155 85 70
Age (years) 30.3 ± 8.0 29.5 ± 7.3 31.2 ± 8.7
Educational years 13.4 ± 2.5 13.6 ± 2.7 13.1 ± 2.2
Female (%) 68.4 63.5 74.3
In employment (%) 59.4 56.5 62.9
Married (%) 38.7 38.8 38.6




HAMD scores 23.4 ± 4.0 23.2 ± 3.9 23.6 ± 4.1
Abbreviation: HAMD Hamilton Depression Rating scale.
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After the subjects were enrolled, they were treated for
four weeks with venlafaxine extended-release, one 75 mg
capsule per day. Because insomnia is a common com-
plaint in patients with MDD, zolpidem (10 mg per tab-
let) was prescribed as needed at night only in the first
2 weeks of treatment, with a total amount ≤6 tablets.
Four weeks later, the same scales were administered.
The HAMD was re-evaluated by the same psychiatrist.
Only subjects who complied with venlafaxine extended-
release treatment ≥80% (total capsules that the subject
took/total days) were included in the post-treatment
analyses.
Statistical methods
All statistical analyses were performed using SPSS for
Windows 12.0 (SPSS Inc., Chicago, IL, USA). The inde-
pendent t test, paired t test, Pearson’s correlation, and
Chi-square test were used in appropriate situations.
Four regression models were used to investigate the im-
pacts of migraine and anxiety disorders on PPS after con-
trolling for the HAMD scores and demographic variables.
The first and second models, performed by multiple linear
regressions with forward selection, investigated the im-
pacts of migraine and anxiety disorders on pain intensities
at baseline and post-treatment, respectively. The third and
fourth models, performed by logistic regressions with for-
ward selection, investigated the impacts of migraine and
anxiety disorders on treatment response (IP ≥ 50) and full
remission (IP = 100) of pain intensities, respectively. The
first model investigated the impacts of migraine and anx-
iety disorders at baseline; therefore, the total subjects at
baseline (N = 155) were used for analysis. The second to
fourth models investigated the impacts of migraine and
anxiety disorders post-treatment; therefore, only patients
with good compliance (N = 85) were used. In the first and
second models, the dependent variables were VAS scores
(pain intensities of each pain) at baseline and post-
treatment, respectively. In the third and fourth models,
the dependent variables were treatment response and full
remission, respectively. For the four regression models,
the independent variables included five demographic vari-
ables (age, gender, educational years, marital status, and
employment status), migraine, anxiety disorders, and the
severity of depression (HAMD scores at baseline for the
first, third, and fourth models and post-treatment for the
second model). In all statistical analyses, a two-tailed P
value <0.05 was considered statistically significant.
Results
Subjects
During the study period, 155 patients (49 men, 106 women)
agreed to participate. Among them, 16 patients had been
treated with antidepressants or other psychotropic drugsand 13 and 3 patients had quit these medications for at least
three months and six weeks, respectively, before enrollment.
Six patients had a history of alcohol abuse and all of them
had achieved full remission for at least 3 months.
Table 1 shows their demographic variables. Among
155 patients, 85 (54.8%) subjects with good compliance
(venlafaxine treatment ≥80% compliance) were included
in the post-treatment analyses (treatment group). The
mean amount of zolpidem taken during the first two-
week treatment period was 2.1 ± 2.4 tablets. The other
70 subjects (withdrawal group) included 22 subjects who
had poor compliance (compliance <80%) or were shifted
to other antidepressants and 48 subjects who did not
finish the treatment. There were no significant differ-
ences at baseline in the five demographic variables, the
percentages of migraine and anxiety comorbidities, and
the HAMD scores between the treatment and withdrawal
groups (Table 1). In analyzing results post-treatment, only
the treatment group was used.
Headache and psychiatric diagnoses
Among the 155 participants, 73 (47.1 %) had migraine,
including 16 patients with chronic migraine (code 1.3),
two with chronic migraine with medication overuse
headache (codes 1.3 and 8.2), 49 with episodic migraine
without aura (code 1.1), and 6 with episodic migraine
both with and without aura (code 1.2). The other 82
subjects included 27 (17.4 %) with probable migraine
without aura (code 1.5.1), one (0.6 %) with chronic
tension-type headache (TTH) (code 2.3), 26 (16.8 %)
with frequent episodic TTH (code 2.2), four (2.6 %) with
infrequent episodic TTH (code 2.1), six (3.9%) with prob-
able episodic TTH (code 2.4), nine (5.8 %) with headache
unspecified (code 14.2), and nine (5.8%) without any
headaches.
Among the 155 patients, 70 (45.2%) subjects had at
least one anxiety comorbidity, including 9.7% (N = 15)
with panic disorder and/or agoraphobia, 24.5% (N = 38)
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11.6% (N = 18) with post-traumatic stress disorder, 6.5%
(N = 10) with obsessive-compulsive disorder, and 7.1%
(N = 11) with GAD.
Among the 85 patients in the treatment group, 44
(51.8%) patients had migraine, including 10 patients with
chronic migraine (code 1.3), two with chronic migraine
with medication overuse headache (codes 1.3 and 8.2),
27 with episodic migraine without aura (code 1.1), and
5 with episodic migraine both with and without aura
(code 1.2), and 43 (50.6%) patients had any one of the
anxiety disorders. There were no significant differences
in the five demographic variables between those with
and without migraine as well as between those with
and without anxiety comorbidities.
Migraine and anxiety disorders are also comorbid with
each other. Compared with MDD patients without mi-
graine, MDD patients with migraine had a higher risk of
comorbidity with any anxiety disorder (63.4% vs. 28.0%,
odds ratio (OR) = 4.64, P <0.001 at baseline; 72.7% vs.
26.8%, OR = 7.27, P <0.001 post-treatment).The percentages of PPS between groups
Table 2 shows the percentages of PPS in the treatment
group between groups. Patients with migraine had sig-
nificantly higher percentages in all PPS at baseline and
post-treatment as compared with patients without mi-
graine. Significant differences between patients with and
without anxiety disorders were noted in terms of head-
ache at baseline and pains in the neck/shoulder and
limbs post-treatment.
Regarding the total number of PPS, patients with mi-
graine had significantly higher numbers of PPS at base-
line (6.3 ± 1.9 vs. 3.9 ± 2.1, P <0.001) and post-treatment
(4.8 ± 2.4 vs. 2.3 ± 2.1, P <0.001) as compared with patientsTable 2 The percentages of pains at baseline and post-4-wee
depressive disordera
Pre-treatment
Groups Migraine Anxiety disor
Yes No OR (95% CI) Yes No OR
Bone and/or Joints 70.5 36.6** 4.1 (1.7-10.2) 55.8 52.4 1.1
Head 100 68.3** - 95.3 73.8** 7.3
Back 81.8 46.3** 5.2 (2.0-13.9) 69.8 59.5 1.6
Abdomen 70.5 36.6** 4.1 (1.7-10.2) 55.8 52.4 1.1
Chest 70.5 41.5** 3.4 (1.4-8.3) 60.5 52.4 1.4
Neck and/or shoulder 97.7 80.5* 10.4 (1.2-87.5) 88.4 90.5 0.8
General muscle 79.5 53.7* 3.4 (1.3-8.7) 69.8 64.3 1.3
Limbs 54.5 24.4** 3.7 (1.5-9.4) 46.5 33.3 1.7
*P <0.05; **P <0.01.
Abbreviations: OR odds ratio, CI confidence interval.
aThe case numbers of the “migraine” and “anxiety disorders” groups were 44 (51.8%without migraine. Similarly, patients with anxiety disor-
ders also tended to have a higher number of PPS at
baseline (5.4 ± 2.3 vs. 4.8 ± 2.3, P = 0.21) and post-
treatment (4.2 ± 2.5 vs. 3.0 ± 2.4, P = 0.02) as compared
with patients without anxiety disorders.
Differences in the severity of depression and pains
between groups
Table 3 shows that the patients with migraine had a sig-
nificantly greater severity of depression and significantly
higher pain intensities and frequencies in all PPS at
baseline and post-treatment as compared with the pa-
tients without migraine, with the exception of chest pain
at baseline.
In patients both with and without migraine, the sever-
ity of depression, the VAS scores and the frequencies of
the eight PPS all showed significant (all P <0.05) im-
provement post-treatment, except for the intensities of
pains in the head and limbs and the frequencies of pains
in bone/joints, head, abdomen, and limbs among pa-
tients without migraine.
Comparing patients with and without anxiety disorders,
significant differences were noted in only the severity of
depression at baseline and the frequencies of pains in the
head, abdomen, and neck/shoulder post-treatment.
For patients with and without any anxiety disorders, the
HAMD scores, VAS scores, and pain frequencies at base-
line showed significant improvement post-treatment, ex-
cept for the intensities of pains in the head and limbs and
the frequency of pain in the limbs among patients without
anxiety disorders.
The correlation of pain intensities and depression
At baseline (N = 155), the HAMD score was significantly
correlated to all pain intensities, with correlation co-k treatment between groups in 85 patients with major
Post-treatment
ders Migraine Anxiety disorders
(95% CI) Yes No OR (95% CI) Yes No OR (95% CI)
(0.5-2.7) 50.0 22.0* 3.6 (1.4-9.2) 46.5 26.2 2.5 (0.98-6.1)
(1.5-35.2) 88.6 53.7** 6.7 (2.2-20.5) 76.7 66.7 1.7 (0.6-4.3)
(0.6-3.8) 63.6 26.8** 4.8 (1.9-12.0) 55.8 35.7 2.3 (0.95-5.4)
(0.5-2.7) 50.0 24.4* 3.1 (1.2-7.8) 41.9 33.3 1.4 (0.6-3.5)
(0.6-3.3) 43.2 12.2** 5.5 (1.8-16.6) 30.2 26.2 1.2 (0.5-3.1)
(0.2-3.2) 90.9 53.7** 8.6 (2.6-28.6) 83.7 61.9* 3.2 (1.1-8.8)
(0.5-3.2) 56.8 26.8** 3.6 (1.4-8.9) 51.2 33.3 2.1 (0.9-5.0)
(0.7-4.2) 36.4 14.6* 3.3 (1.2-9.6) 37.2 14.3* 3.6 (1.2-10.3)
) and 43 (50.6%), respectively.
Table 3 The severities of pain indices and depression at baseline and post-4-week treatment between groups in 85
patients with major depressive disordera
Pre-treatment Post-treatment
Migraine Anxiety disorders Migraine Anxiety disorders
Yes (N = 44) No (N = 41) Yes (N = 43) No (N = 42) Yes (N = 44) No (N = 41) Yes (N = 43) No (N = 4 2)
HAMD scores 24.2 ± 3.9 22.2 ± 3.5* 24.1 ± 4.1 22.3 ± 3.5* 14.8 ± 6.6 10.6 ± 5.8** 13.4 ± 7.0 12.1 ± 6.0
Bone and/or joints Intensity 3.7 ± 3.2 1.3 ± 3.1** 3.1 ± 3.3 1.9 ± 2.5 2.1 ± 3.1 0.5 ± 1.0** 1.6 ± 2.7 1.0 ± 2.2
Frequency 3.1 ± 2.9 1.2 ± 2.1** 2.7 ± 3.0 1.6 ± 2.2 1.7 ± 2.4 0.7 ± 1.7* 1.6 ± 2.4 0.8 ± 1.8
Head Intensity 6.4 ± 2.6 2.4 ± 2.5** 5.1 ± 3.0 3.8 ± 2.4 4.0 ± 3.2 2.0 ± 2.5** 3.1 ± 3.2 2.9 ± 3.0
Frequency 4.7 ± 2.4 1.8 ± 2.1** 3.7 ± 2.6 2.8 ± 2.8 3.2 ± 2.4 1.1 ± 1.4** 2.8 ± 2.5 1.6 ± 1.8*
Back Intensity 4.3 ± 3.0 1.6 ± 2.3** 3.6 ± 3.3 2.5 ± 2.6 2.1 ± 2.7 0.7 ± 1.4** 1.6 ± 2.3 1.2 ± 2.2
Frequency 3.9 ± 2.8 1.9 ± 2.5** 3.1 ± 2.9 2.7 ± 2.8 2.1 ± 2.4 0.9 ± 2.0* 1.8 ± 2.3 1.2 ± 2.2
Abdomen Intensity 2.7 ± 2.7 1.2 ± 1.9** 2.2 ± 2.7 1.7 ± 2.2 1.6 ± 2.2 0.5 ± 1.1** 1.3 ± 2.2 0.8 ± 1.4
Frequency 2.6 ± 2.5 1.0 ± 1.7** 2.3 ± 2.6 1.4 ± 1.9 1.5 ± 2.1 0.5 ± 1.3** 1.5 ± 2.3 0.6 ± 0.9*
Chest Intensity 3.1 ± 3.4 2.0 ± 2.9 2.7 ± 3.3 2.4 ± 3.2 1.8 ± 2.8 0.3 ± 0.8** 1.2 ± 2.4 0.9 ± 2.1
Frequency 2.3 ± 2.5 1.5 ± 2.4 1.8 ± 2.3 2.0 ± 2.7 1.1 ± 1.7 0.2 ± 0.6** 0.7 ± 1.4 0.7 ± 1.3
Neck and/or shoulder Intensity 6.9 ± 2.6 3.7 ± 3.2** 5.9 ± 3.5 4.8 ± 3.0 4.1 ± 3.4 1.6 ± 2.1** 3.4 ± 3.3 2.4 ± 2.8
Frequency 5.9 ± 2.0 3.8 ± 3.0** 5.1 ± 2.8 4.7 ± 2.7 4.2 ± 2.4 2.4 ± 2.9** 4.0 ± 2.7 2.7 ± 2.8*
General muscle Intensity 4.4 ± 3.1 1.9 ± 2.6** 3.4 ± 3.0 3.0 ± 3.3 2.5 ± 3.3 0.8 ± 1.7** 1.9 ± 2.9 1.5 ± 2.6
Frequency 4.0 ± 3.0 2.1 ± 2.6** 3.5 ± 3.1 2.5 ± 2.7 2.3 ± 2.9 1.0 ± 2.2* 2.0 ± 2.9 1.3 ± 2.4
Limbs Intensity 2.1 ± 2.5 0.8 ± 1.8** 1.7 ± 2.5 1.2 ± 2.2 1.1 ± 2.0 0.3 ± 1.0* 0.9 ± 1.7 0.5 ± 1.5
Frequency 1.9 ± 2.5 0.8 ± 1.9* 1.8 ± 2.6 1.0 ± 1.8 1.0 ± 1.7 0.4 ± 1.2* 0.9 ± 1.6 0.5 ± 1.4
*P <0.05; **P <0.01.
Abbreviation: HAMD Hamilton Depression Rating scale.
aPain intensity and frequency were measured using a 0–10 visual analog scale and number of pain days in the past week, respectively.
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dominal pain). Post-treatment (N = 85), the correlation
co-efficiencies (all P <0.05) ranged from 0.35 (pain in
bone/joint) to 0.23 (back pain). The correlations of age
and educational levels with all pain intensities were
not significant at baseline and post-treatment.Table 4 The percentages of treatment response and full remis
with major depressive disorderb,c
Treatment response
Groups Migraine Anxiety disord
Yes No OR (95% CI) Yes No OR (
Bone and/or joints 67.7 66.7 1.1 (0.3-3.9) 70.8 63.6 1.4
Head 45.5 60.7 0.5 (0.2-1.4) 53.7 48.8 1.2
Back 69.4 73.7 0.8 (0.2-2.8) 73.3 68.0 1.3
Abdomen 61.3 86.7a 0.2 (0.05-1.3) 58.3 81.8 0.3
Chest 48.4 94.1** 0.1 (0.01-0.5) 65.4 63.6 1.1
Neck and/or shoulder 46.5 60.6 0.6 (0.2-1.4) 47.4 57.9 0.7
General muscle 62.9 63.6 0.97 (0.3-2.9) 63.3 63.0 1.0
Limbs 62.5 90.0 0.2 (0.02-1.7) 65.0 78.6 0.5
*P <0.05; **P <0.01.
Abbreviation: CI confidence interval.
aBorderline significance (P =0.1-0.05).
bThe case numbers of the “migraine” and “anxiety disorders” groups were 44 (51.8%
cTreatment response and full remission were defined as an improvement percentagDifferences in the percentages of treatment response and
full remission between groups
Table 4 shows the trend that patients with migraine had
lower percentages of treatment response and full remis-
sion in the PPS, except for pain in bone/joints. Statisti-
cally significant differences between patients with andsion post-4-week treatment between groups in 85 patients
Full remission
ers Migraine Anxiety disorders
95% CI) Yes No OR (95% CI) Yes No OR (95% CI)
(0.4-4.8) 45.2 60.0 0.5 (0.2-1.9) 45.8 54.5 0.7 (0.2-2.3)
(0.5-3.1) 11.4 39.3** 0.2 (0.06-0.7) 19.5 25.8 0.7 (0.2-2.1)
(0.4-4.2) 36.1 63.2a 0.3 (0.1-1.0) 40.0 52.0 0.6 (0.2-1.8)
(0.1-1.2) 38.7 66.7 0.3 (0.1-1.2) 33.3 63.6a 0.3 (0.1-0.96)
(0.3-3.5) 41.9 76.5* 0.2 (0.06-0.8) 53.8 54.5 0.97 (0.3-3.0)
(0.3-1.6) 7.0 39.4** 0.1 (0.03-0.5) 10.5 31.6* 0.3 (0.1-0.9)
(0.3-3.0) 37.1 54.5 0.5 (0.2-1.5) 33.3 55.6 0.4 (0.1-1.2)
(0.1-2.4) 41.7 70.0 0.3 (0.06-1.5) 35.0 71.4a 0.2 (0.05-0.95)
) and 43 (50.6%), respectively.
e of pain intensities > = 50 and =100, respectively.
Hung et al. The Journal of Headache and Pain 2014, 15:73 Page 6 of 9
http://www.thejournalofheadacheandpain.com/content/15/1/73without migraine were noted in chest pain for treatment
response and in chest pain, headache, and neck/shoulder
pain for full remission.
Patients with anxiety disorders also tended to have
lower percentages of full remission post-treatment, and
a significant difference was only noted in neck/ shoulder
pain (Table 4).Table 5 Independent factors predicting the intensities of pain
Locations Time points Independent variab



































Abbreviations: HAMD Hamilton Depression Rating scale, post Tx post-four-week trea
aMultiple linear regressions were used in this Table.
bThe case numbers included in the analyses at baseline and post-treatment were 1
cData in boldface indicate data at baseline.The impacts of migraine on PPS at baseline and post-
treatment
The first regression model demonstrated that migraine in-
dependently predicted the intensities of the eight PPS at
baseline, after controlling for the demographic variables
and HAMD scores (Table 5). Moreover, the impacts of
migraine might be greater than the severity of depression,s at baseline and post-4-week treatmenta,b,c
le Beta R2 change t P
0.32 0.16 4.26 < 0.01
0.28 0.07 3.83 < 0.01
0.25 0.12 2.38 0.02
0.27 0.06 2.54 0.01
−0.20 0.04 −2.01 0.048
0.46 0.29 6.70 < 0.01
0.25 0.06 3.68 < 0.01
0.58 0.33 6.33 < 0.01
0.17 0.36 4.75 < 0.01
0.03 0.19 2.48 0.01
0.42 0.24 4.54 < 0.01
0.37 0.09 4.05 < 0.01
0.22 0.04 2.36 0.01
−0.21 0.04 −2.24 0.03
0.28 0.08 3.63 < 0.01
0.34 0.12 3.34 < 0.01
0.20 0.04 1.99 0.05
0.32 0.13 4.06 < 0.01
0.16 0.01 2.00 0.048
0.38 0.20 3.74 < 0.01
0.23 0.05 2.26 0.03
0.39 0.15 5.25 < 0.01
0.46 0.30 5.02 < 0.01
0.27 0.06 2.92 < 0.01
−0.18 0.03 −2.03 0.046
0.32 0.16 4.23 < 0.01
0.28 0.07 3.69 < 0.01
0.27 0.51 5.59 < 0.01
0.04 0.20 2.17 0.03
0.26 0.11 3.43 < 0.01
0.22 0.04 2.87 < 0.01
−0.19 0.04 −2.54 0.01
0.36 0.08 3.36 < 0.01
0.26 0.08 2.65 0.01
−0.22 0.04 −2.06 0.04
tment.
55 and 85, respectively.
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gression model demonstrated that migraine independently
predicted the intensities of pains in bone/joints, back,
chest, and neck/shoulder post-treatment. In the two re-
gression models, anxiety disorders were not entered.
Factors independently predicting the treatment response
and full remission
The third and fourth (logistic) regression models demon-
strated that migraine independently predicted the treatment
response for chest pain (OR = 0.06, 95% CI = 0.01-0.50,
P= 0.01) and full remission for pains in the head (OR= 0.15,
95% CI = 0.04-0.56, P = 0.01), chest (OR = 0.22, 95%
CI = 0.06-0.84, P = 0.03), and neck/shoulder (OR = 0.12,
95% CI = 0.03-0.45, P <0.01) after controlling for the
demographic variables and HAMD score at baseline. Anx-
iety disorders independently predicted full remission for
pains in the abdomen (OR = 0.29, 95% CI = 0.09-0.96, P =
0.04) and limbs (OR = 0.22, 95% CI = 0.05-0.95, P = 0.04).
Discussion
Compared with patients without migraine, patients with
migraine had a significantly higher number of PPS and
higher pain intensities and frequencies in all PPS at
baseline and post-treatment, with the exception of chest
pain at baseline. After controlling for demographic vari-
ables, depression, and anxiety comorbidities, migraine
independently predicted all PPS at baseline and four
pains post-treatment (Table 5). These results implied
two issues. 1) Migraine is an important factor related to
PPS among patients with MDD. Although the severity of
depression was significantly correlated to pain inten-
sities, it could not explain all pain intensities. 2) The im-
pacts of migraine on PPS might be greater than those of
anxiety disorders among patients with MDD. However,
this might need more evidence. Migraine and anxiety
disorders are often comorbid with each other [29,30].
Anxiety disorders are also comorbid with PPS [19-21].
Therefore, investigation of PPS among depressive and
anxiety disorders should consider the impacts of migraine.
The result that the impacts of migraine on most PPS at
baseline were greater than the severity of depression
might be explained the following hypothesis. At baseline,
subjects with migraine all suffered from headache (Table 2)
and had a high headache intensity (VAS = 6.4 ± 2.6) and
frequency (4.7 ± 2.4 days) in the past week (Table 3).
Migraine is often accompanied with signs of increased
intracranial and extracranial mechanical sensitivities
and related to somatosensory amplification [31,32]. Re-
peated migraine attacks might cause an effect similar
to central sensitization, which is related to allodynia,
hyperalgesia and spontaneous pain and might allow sub-
jects to become more sensitive to other PPS [22,31].
Moreover, headache intensity is related to muscloskeletalsymptoms [33]. Post-treatment, the headache intensity
and frequency of migraine were decreased. The effect of
central sensitization resulting from headache might be de-
creased. Therefore, the impact of depression (HAMD
scores post-treatment) on PPS might exceed the impact of
migraine. In future studies, the impacts of headache at-
tacks on other PPS might need to be further clarified.
There is a possibility that treatment of migraine might
help to improve headache attacks, then improve other
PPS. The patients with migraine had significantly higher
HAMD scores at baseline and post-treatment than the pa-
tients without migraine (Table 3). A trend was noted that
the patients with migraine had a smaller reduction in the
HAMD score post-treatment (9.4 points vs. 11.6 points
for the migraine group vs. non-migraine group) as
compared with the patients without migraine, and the
difference in the HAMD scores between the migraine
and non-migraine groups became greater (2.0 points at
baseline and 4.2 points post-treatment) (Table 3). These
results implied the possibility that migraine might be a
factor related to a poorer prognosis of depression. How-
ever, more evidence is still needed. Moreover, the impacts
of anxiety disorders should also be further studied.
After controlling for demographic variables and de-
pression at baseline, migraine independently predicted a
lower percentage of treatment response in chest pain
and of full remission in pains in the chest, head, and
neck/shoulder. This demonstrated that migraine also has
negative impacts on the treatment prognosis of PPS. Pa-
tients with noncardiac chest pain are often comorbid
with depression and anxiety disorders [19,20]. Patients
with migraine have a higher risk of chest pain, and a link
between migraine and vasospastic disorders might be
one of the possible reasons [34]. The possible reasons
for which migraine has a negative impact on the recov-
ery of chest pain should be investigated in future studies.
Migraine was also an independent factor predicting a
poor treatment prognosis of neck/shoulder pain. Head-
ache is a strong factor associated with neck/shoulder
soreness and musculoskeletal symptoms [33]. Moreover,
patients with migraine have muscle hyperalgesia and de-
creased pressure pain thresholds in the neck/shoulder
[35]. These might be the possible reasons for which mi-
graine has a negative impact on the recovery of neck/
shoulder pain post-treatment. Comorbidity with anxiety
disorders was an independent factor related to poor
treatment remission of abdominal pain. Recurrent ab-
dominal pain is associated with anxiety disorders [36]. In
fact, patients with migraine also have a higher risk of ab-
dominal pain [37]. The interaction of abdominal pain,
anxiety disorders, and migraine might need to be clarified.
Several methodological issues or limitations need to be
addressed. 1) The analyses post-treatment only included
patients with good compliance. Only 85 (54.8%) subjects
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analyses. Although there were no significant differences in
the demographic variables and the HAMD scores between
the treatment and withdrawal groups, possible bias was
unable to be fully excluded, because patients with a poor
treatment response might be more likely to drop out [38].
2) This study had no placebo-controlled group because the
major purpose was not to investigate the efficacy of venla-
faxine. Therefore, the improvement of PPS and depression
might be mixed with multiple effects. 3) The headache pa-
rameters in the past week were recalled by the patients.
Collecting data prospectively using a headache diary might
be more reliable. However, withholding pharmacological
treatment while prospectively observing headache parame-
ters might result in ethical problems owing to the suicidal
risk. 4) This study only observed the four-week treatment
response, because four-week treatment may be a milestone
after which a treatment response can be observed [39]. 5)
Although the total mean amount of zolpidem taken in the
first two weeks was only 2.1 ± 2.4 tablets, possible bias
resulting from zolpidem usage could not be excluded. 6)
One previous study demonstrated that MDD patients with
chronic migraine had the worst bodily pain on the SF-36,
followed by episodic migraine [40]. Therefore, chronic mi-
graine might have a greater contribution to influence PPS
and treatment response than episodic migraine. In future
study, a larger sample size should be used to compare the
impacts of chronic migraine, episodic migraine, TTH, and
other headache types on PPS and treatment response.Conclusion
After controlling for depression, anxiety comorbidities,
and demographic variables, migraine independently pre-
dicted the eight PPS at baseline and four PPS post-
treatment. Moreover, migraine also independently pre-
dicted poor treatment prognosis of pains in the chest,
head, and neck/shoulder. Anxiety disorders predicted
poor treatment prognosis of pains in the abdomen and
limbs. Depression, anxiety, migraine, and PPS might inter-
act with each other. The impacts of migraine and anxiety
disorders should be considered in investigating PPS
among patients with MDD. Integration of the treat-
ment for migraine and anxiety disorders into the treat-
ment of depression might help improve PPS and the
prognosis of MDD.
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